T1	intervention 10 20	everolimus
T2	eligibility 163 290	postmenopausal women with estrogen receptor-positive breast cancer progressing despite nonsteroidal aromatase inhibitor therapy
T5	outcome-Measure 803 841	changes in bone turnover marker levels
T6	outcome-Measure 845 885	baseline and progressive disease in bone
T7	No-of-participants 1061 1064	724
T8	outcome-Measure 1195 1220	progression-free survival
T9	duration 1164 1173	18 months
T10	outcome 991 1023	Baseline disease characteristics
T11	intervention-value 1104 1109	43.9%
T12	control-value 1125 1130	54.0%
T13	outcome 1428 1446	Bone marker levels
T14	outcome 1550 1606	cumulative incidence rate of progressive disease in bone
T15	outcome 1641 1668	Bone-related adverse events
T3	control 745 770	placebo (exemestane only)
T4	intervention-value 1715 1719	3.3%
T16	control-value 1735 1739	4.2%
